These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26123413)

  • 21. Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.
    Pottegård A; Friis S; Stürmer T; Hallas J; Bahmanyar S
    Basic Clin Pharmacol Toxicol; 2018 May; 122(5):451-459. PubMed ID: 29265740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing causal effects in observational survival data using propensity score matching design.
    Lu B; Cai D; Tong X
    Stat Med; 2018 May; 37(11):1846-1858. PubMed ID: 29399833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjustment for time-dependent unmeasured confounders in marginal structural Cox models using validation sample data.
    Burne RM; Abrahamowicz M
    Stat Methods Med Res; 2019 Feb; 28(2):357-371. PubMed ID: 28835193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies.
    Barrowman MA; Peek N; Lambie M; Martin GP; Sperrin M
    BMC Med Res Methodol; 2019 Jul; 19(1):166. PubMed ID: 31366331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
    Khunti K; Knighton P; Zaccardi F; Bakhai C; Barron E; Holman N; Kar P; Meace C; Sattar N; Sharp S; Wareham NJ; Weaver A; Woch E; Young B; Valabhji J
    Lancet Diabetes Endocrinol; 2021 May; 9(5):293-303. PubMed ID: 33798464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.
    Varas-Lorenzo C; Margulis AV; Pladevall M; Riera-Guardia N; Calingaert B; Hazell L; Romio S; Perez-Gutthann S
    BMC Cardiovasc Disord; 2014 Sep; 14():129. PubMed ID: 25260374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.
    Farmer RE; Ford D; Forbes HJ; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
    Int J Epidemiol; 2017 Apr; 46(2):728-744. PubMed ID: 28031313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
    Karim ME; Gustafson P; Petkau J; Tremlett H;
    Am J Epidemiol; 2016 Aug; 184(4):325-35. PubMed ID: 27455963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control.
    Wood ME; Lapane KL; van Gelder MMHJ; Rai D; Nordeng HME
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):140-147. PubMed ID: 29044735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of methods for estimating the attributable risk in the context of survival analysis.
    Gassama M; Bénichou J; Dartois L; Thiébaut AC
    BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events.
    Hazelbag CM; Klungel OH; van Staa TP; de Boer A; Groenwold RH
    Ann Epidemiol; 2015 Aug; 25(8):590-6. PubMed ID: 25935711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.
    Bykov K; He M; Franklin JM; Garry EM; Seeger JD; Patorno E
    Diabetes Obes Metab; 2019 Sep; 21(9):2029-2038. PubMed ID: 31062453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling.
    Neugebauer R; Fireman B; Roy JA; Raebel MA; Nichols GA; O'Connor PJ
    J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S99-109. PubMed ID: 23849160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale.
    Cologne J; Hsu WL; Abbott RD; Ohishi W; Grant EJ; Fujiwara S; Cullings HM
    Epidemiology; 2012 Jul; 23(4):565-73. PubMed ID: 22517300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study.
    Cho IS; Chae YR; Kim JH; Yoo HR; Jang SY; Kim GR; Nam CM
    BMC Med Res Methodol; 2017 Aug; 17(1):126. PubMed ID: 28830373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Alzheimer Disease and Cancer With Evaluation of Study Biases: A Systematic Review and Meta-analysis.
    Ospina-Romero M; Glymour MM; Hayes-Larson E; Mayeda ER; Graff RE; Brenowitz WD; Ackley SF; Witte JS; Kobayashi LC
    JAMA Netw Open; 2020 Nov; 3(11):e2025515. PubMed ID: 33185677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.
    A'Hern RP
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):e75-e80. PubMed ID: 29776805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.